A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

← catalyst calendar

NCT07787182 · readout ≤ 522 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

68estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-26

Dates

each axis at the precision it was filed, with the registry's own basis

Date	Filed	Basis	What it is
Start	Sep 2026	estimated	When the study began enrolling
Primary completion	Jan 2028	estimated	The date the last participant is measured for the primary outcome — the readout window
Study completion	Jan 2028	estimated	The whole study's end, after follow-up
First posted	2026-08-26	actual	When this record first appeared on the registry
Results posted	—		When the sponsor posted results to the registry
Record updated	2026-08-26	actual	The sponsor's own last edit to this record — every projection above is as current as this date

Date

Filed

Basis

What it is

Start

Sep 2026

estimated

When the study began enrolling

Primary completion

Jan 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2028

estimated

The whole study's end, after follow-up

First posted

2026-08-26

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-26

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Healthy Volunteers
Alzheimer Disease
Amyloid
Plaque, Amyloid

Interventions

Drug: LY4405094
Drug: LY4405094
Drug: Placebo
Drug: Placebo
Other: Florbetapir F18
Other: Florbetaben F 18

Primary outcome

what the primary-completion date above is the date OF

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

measured Baseline up to 25 Weeks

LLY · their whole pipeline · Alzheimer's Disease readouts · Congress trades in LLY · Executive-branch trades in LLY

LLY's other studiesmost recently updated first

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Phase 3 · Active, not recruiting
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease Phase 1 · Not yet recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults Phase 3 · Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) Phase 2 · Recruiting
A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants Phase 1 · Completed

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed